Author

Renske W. M. Pauwels

Observed names: Pauwels, Renske, Pauwels, Renske W. M., Pauwels, Renske W.M., R Pauwels, R W M Pauwels, R.W.M. Pauwels, Renske Pauwels, Renske W M Pauwels, Renske W. Pauwels, Renske W.M. Pauwels, Renske Wilhelmina Maria Pauwels

Institution: Erasmus MC

Observed institution: Erasmus MC

ORCID: 0000-0002-2118-5687

Observed ORCID: 0000-0002-2118-5687

OpenAlex ID: A5074453001

Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

2021 · Renske W.M. Pauwels, C. Janneke van der Woude, et al. · Clinical Gastroenterology and Hepatology · 42

PDF

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

2023 · Reinier C A van Linschoten, Fenna M Jansen, et al. · The Lancet. Gastroenterology & hepatology · 20

PDF

Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice

2023 · Elisa Proietti, Renske W.M. Pauwels, et al. · International Journal of Tryptophan Research · 18

PDF

Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction

2022 · Elisa Proietti, Renske W M Pauwels, et al. · Inflammatory Bowel Diseases · 17

PDF

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease

2021 · Renske W M Pauwels, Elisa Proietti, et al. · Inflammatory Bowel Diseases · 15

PDF

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

2020 · Renske W. M. Pauwels, Christien J. van der Woude, et al. · Therapeutic Advances in Gastroenterology · 14

PDF

Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice

2020 · Renske Wilhelmina Maria Pauwels, Annemarie Charlotte de Vries, et al. · Journal of Gastroenterology and Hepatology · 13

PDF

Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

2023 · Sebastiaan ten Bokkel Huinink, Doranne Thomassen, et al. · Journal of Crohn s and Colitis · 7

PDF

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study

2020 · L J T Smits, R W M Pauwels, et al. · BMJ Open · 7

PDF

Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn’s disease

2023 · Renske W. M. Pauwels, Sebastiaan ten Bokkel Huinink, et al. · Scandinavian Journal of Gastroenterology · 6

PDF

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial

2023 · Fenna M Jansen, Reinier C A van Linschoten, et al. · Journal of Crohn s and Colitis · 4

PDF

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

2024 · Reinier C. A. van Linschoten, Fenna M. Jansen, et al. · Digestive Diseases and Sciences · 2

PDF

P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease

2017 · R.W.M. Pauwels, A.C. De Vries, et al. · Journal of Crohn s and Colitis · 2

Mo1887 – Ustekinumab Endoscopic Response At Week 16 is Associated with Early Normalization of Fecal Calprotectin After Induction

2019 · Renske W. Pauwels, Annemarie C. de Vries, et al. · Gastroenterology · 1

PDF

P138 Prediction model to safely cease anti-TNF therapy in Crohn’s disease: individual patient data meta-analysis (IPD-MA)

2019 · R W M Pauwels, C J van der Woude, et al. · Journal of Crohn s and Colitis · 1

Comment on “Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease”

2018 · Renske W M Pauwels, Annemarie C de Vries, et al. · Inflammatory Bowel Diseases · 1

Vedolizumab Induces Significantly Higher Endoscopic Remission Rates at Week 16 in Ulcerative Colitis as Compared to Crohn's Disease

2017 · Renske Pauwels, Annemarie C. de Vries, et al. · Gastroenterology · 1

P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial

2023 · R Van Linschoten, F Jansen, et al. · Journal of Crohn s and Colitis

PDF

P555 Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction

2022 · E Proietti, A Bayoumy, et al. · Journal of Crohn s and Colitis

PDF

537 – Fecal Calprotectin is an Early Predictor of Endoscopic Response and Histological Remission After the Start of Vedolizumab

2019 · Renske W. Pauwels, Annemarie C. de Vries, et al. · Gastroenterology

P362 Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab

2019 · R W M Pauwels, A C de Vries, et al. · Journal of Crohn s and Colitis

P414 Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction

2019 · R W M Pauwels, A C de Vries, et al. · Journal of Crohn s and Colitis

P433 Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy

2018 · R W M Pauwels, A C De Vries, et al. · Journal of Crohn s and Colitis

Works count: 34

Citation count: 213

H-index: 8

I10-index: 8